��������

Michelle LeRoux Williams, Ph.D. is the Chief Scientific Officer of Aziyo. Dr. Williams was one of the founders of Aziyo Biologics and has over 20 years of experience in innovative product development. Previously, Dr. Williams served as Chief Scientific Officer of Osiris Therapeutics, where she invented Osteocel®, the world’s first commercially available stem cell product, led the team that obtained regulatory approval of the world’s first stem cell drug approval (remestemcel-L), and oversaw the development of successful stem cell products, including Grafix® and Cartiform®.

Dr. Williams is a fellow at the American Institute for Medical and Biological Engineering (AIMBE) and an internationally recognized expert in biologics and cell therapy. Dr. Williams earned a Bachelor’s degree from Rice University, a Ph.D. in biomedical engineering from Duke University, and completed her post-doctorate training at Columbia University. She also serves on the Grants Working Group of the California Institute of Regenerative Medicine, the state’s $5.5 billion stem cell agency.